Bio Blast Pharma Receives New Coverage from Analysts at Roth Capital (ORPN)
Equities researchers at Roth Capital assumed coverage on shares of Bio Blast Pharma (NASDAQ:ORPN) in a research report issued on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Separately, analysts at Oppenheimer initiated coverage on shares of Bio Blast Pharma in a research note on Monday. They set an “outperform” rating on the stock.
Bio Blast Pharma (NASDAQ:ORPN) opened at 7.68 on Monday. Bio Blast Pharma has a 52-week low of $6.61 and a 52-week high of $11.00. The stock has a 50-day moving average of $7.49 and a 200-day moving average of $7.49. The company’s market cap is $109.3 million.
Receive News & Ratings for Bio Blast Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.